Study: Critical Diagnostics heart failure biomarker beats out BG Medicine test; BioMarker Strategies lands $1.5M grant for melanoma diagnostic;

> Critical Diagnostics published a study finding that its myocardial fibrosis biomarker, ST2, for long-term heart failure risk performed better than BG Medicine's Galectin-3. Release

> Life Technologies ($LIFE) says it will distribute Advanced Cell Diagnostics' fluorescent RNAscope biomarkers technology to the research market, according to GenomeWeb. Item (sub. req.) 

> Baltimore, MD-based BioMarker Strategies has won a $1.5 million Small Business Innovation Research Phase II award from the National Cancer Institute to further develop its companion diagnostic for melanoma. Item (sub. req.)

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.